Latest research on Eprex

Human erythropoietin (recombinant), produced by CHO cells.

Eprex side effects

Because Epogin at 4.4 μM showed a saturation of hematopoietic activity, the data of Epogin at 1.4 μM were used for the comparison of synthetic EPO glycoforms 2 to 6. [source, 2016]
If the three N-glycosylation positions of Epogin have three homogeneous tri- or tetraantennary sialyloligosaccharides, the activity of the hematocrit might be increased. [source, 2016]
Because of the concern for increasing immunogenicity, the subsequent formulations of Eprex replaced uncoated rubber stoppers with fluororesin-coated stoppers and the polysorbate was removed [3]. [source, 2015]
Although the dose of Eprex (erythropoietin) did not change during the study, the level of hemoglobin was increased after active and passive intradialytic exercise programs. [source, 2015]
Using Epogen can lead to death or other serious side effects’ [14]. [source, 2013]
In conclusion, Procrit and other erythropoiesis stimulating drugs, while intended for the treatment of anemia due to the effect of concomitantly administered chemotherapy, can cause significant morbidity and mortality with an increased risk of cardiovascular events, gastrointestinal bleeding, thromboembolism and stroke. [source, 2013]
As before with Neupogen, combining A(1-7) with Epogen has hematological effects outside of the erythroid lineage in that the concentration of circulating neutrophils was increased with this combination. [source, 2013]
However, in studies in rats these prohypertensive effects of Epogen were offset by increased NO generation in the endothelial cells of the kidney [33]. [source, 2011]
These cross-reactive antibodies caused 175 patients receiving this new formulation of Eprex to develop pure red cell aplasia between 1998 and 2004 [17]. [source, 2011]
The cause of the increased immunogenicity of Eprex is still under debate (6–9), although the increased tendency for aggregation in the new formulation is considered the most likely explanation, together with the subcutaneous route of administration (10). [source, 2010]